Literature DB >> 10485075

MR imaging of pancreatic lesions. Comparison of manganese-DPDP and gadolinium chelate.

S J Diehl1, K J Lehmann, J Gaa, S McGill, V Hoffmann, M Georgi.   

Abstract

RATIONALE AND
OBJECTIVES: To compare manganese-DPDP-enhanced and gadolinium-DTPA-enhanced MR imaging in patients suspected of having pancreatic cancer.
METHODS: Fifteen patients who underwent MR imaging for suspected pancreatic cancer and received gadolinium-DTPA took part in a clinical phase III trial in which the efficacy of manganese-DPDP for detection of pancreatic cancer was evaluated. T1-weighted gradient-echo (GRE) images with and without fat suppression were used. Signal-to-noise ratio and contrast-to-noise ratio were calculated before and after the administration of each contrast agent. Image quality was assessed using a four-step score; delineation of the normal pancreas was assessed by two readers in consensus.
RESULTS: In terms of pancreatic signal-to-noise ratio, only gadolinium-DTPA-enhanced fat-suppressed and non-fat-suppressed GRE imaging showed a significant (P < 0.001) increase (72% and 61%, respectively). In the patients with a focal pancreatic lesion (n = 14), a significant increase in contrast-to-noise ratio was found only in manganese-DPDP-enhanced GRE imaging without (106%) and with (82%) fat saturation. Qualitative image analysis demonstrated a significant improvement of manganese-DPDP-enhanced fat-suppressed MR images in delineating the pancreatic parenchyma (P < 0.01) as well as pancreatic tumors (P < 0.01).
CONCLUSIONS: T1-weighted manganese-DPDP-enhanced GRE imaging with fat saturation should be regarded as the most suitable combination for detecting a pancreatic lesion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485075     DOI: 10.1097/00004424-199909000-00007

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  7 in total

1.  Gd(III)-Dithiolane Gold Nanoparticles for T1-Weighted Magnetic Resonance Imaging of the Pancreas.

Authors:  Robert J Holbrook; Nikhil Rammohan; Matthew W Rotz; Keith W MacRenaris; Adam T Preslar; Thomas J Meade
Journal:  Nano Lett       Date:  2016-04-20       Impact factor: 11.189

Review 2.  Pancreatic adenocarcinoma.

Authors:  Wolfgang Schima; Ahmed Ba-Ssalamah; Claus Kölblinger; Christiane Kulinna-Cosentini; Andreas Puespoek; Peter Götzinger
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

3.  Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.

Authors:  Piero Boraschi; Francescamaria Donati; Roberto Gigoni; Davide Caramella; Ugo Boggi; Fabio Falaschi; Carlo Bartolozzi
Journal:  Eur Radiol       Date:  2006-01-19       Impact factor: 5.315

4.  Diagnosis of pancreatic cancer.

Authors:  Fumihiko Miura; Tadahiro Takada; Hodaka Amano; Masahiro Yoshida; Shigeru Furui; Koji Takeshita
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

5.  Quantitative phase imaging of stromal prognostic markers in pancreatic ductal adenocarcinoma.

Authors:  Michael Fanous; Adib Keikhosravi; Andre Kajdacsy-Balla; Kevin W Eliceiri; Gabriel Popescu
Journal:  Biomed Opt Express       Date:  2020-02-12       Impact factor: 3.732

6.  Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging.

Authors:  Zipeng Zhen; Jin Xie
Journal:  Theranostics       Date:  2012-01-01       Impact factor: 11.556

Review 7.  Manganese-Enhanced Magnetic Resonance Imaging: Overview and Central Nervous System Applications With a Focus on Neurodegeneration.

Authors:  Ryan A Cloyd; Shon A Koren; Jose F Abisambra
Journal:  Front Aging Neurosci       Date:  2018-12-13       Impact factor: 5.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.